Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03111121 · ClinicalTrials.gov registry record · Phase 4
Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy
A Phase 4 study, sponsored by West Virginia University.
- Completed
- Registry status
- Phase 4
- Development phase
- 79
- Enrollment target
NCT03111121: Completed Phase 4 study, sponsored by West Virginia University.
NCT03111121 is a Phase 4 study that has completed, run by West Virginia University. The registered enrollment target is 79 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03111121, a Phase 4 study, has completed, sponsored by West Virginia University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 79 participants
- Enrollment target
Study Summary
Use of Muscle relaxant and reversal with Sugammadex at end of airway procedures will reduce the time to extubation after end of procedure
Primary Outcome
West Virginia University Hospitals use an electronic medical record (EMR) to chart the end of the procedure. When the surgeon states "We are done", always at withdrawal of the scope, extubation begins. From the time we chart end of procedure to the time of extubation is the extubation time. The start and end times for extubation will be recorded in the EMR.
Interventions
- DRUG Sugammadex
- DRUG neostigmine
- DRUG glycopyrrolate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2017-05-04 |
| Est. Completion | 2019-05-30 |
| Phase | Phase 4 |
What the finished NCT03111121 record still lists
NCT03111121 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 3 interventions - of which Sugammadex is the first listed.
NCT03111121 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03111121 about?
NCT03111121 is a clinical study titled "Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy". Use of Muscle relaxant and reversal with Sugammadex at end of airway procedures will reduce the time to extubation after end of procedure
What is the current status of trial NCT03111121?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 79 participants. The study started on 2017-05-04. Estimated completion is 2019-05-30.
What interventions are being tested in trial NCT03111121?
The interventions under investigation include: Sugammadex (DRUG), neostigmine (DRUG), glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT03111121?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03111121's enrollment target sits among peer trials
79 980th of 2000 higher than 1,019 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI